Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?
Kazia Therapeutics Limited (NASDAQ:KZIA) has materially strengthened its financing position, but the clinical case for expanding paxalisib into HR-positive, HER2-negative metastatic breast cancer remains...




